Company profilePharmaceutical#194 of 1,318 in Pakistan✓ No DRAP alerts

TAGMA PHARMA (PVT) LTD.

Pharmaceutical company · 94 brands · 87 molecules

Ranked #18 of 311 companies in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord)

94 registered products 34 pharmaceutical brands 87 distinct molecules 0 DRAP alerts

Company overview

94
registered products
34
pharmaceutical brands
87
distinct molecules
12
therapeutic classes
0
DRAP alerts

TAGMA PHARMA (PVT) LTD. is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 94 product registrations across 87 distinct molecules. It is the 194th largest registrant in Pakistan by product count, and ranks 18th of 311 in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord). Its portfolio is concentrated in Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) and Blood Glucose Lowering Drugs, Excluding Insulin. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by TAGMA

7 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Cardiac Care 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

6
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
20256

Top molecules by brand count

Therapeutic classes

Drugs For Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord) · 8Blood Glucose Lowering Drugs, Excluding Insulin · 3Lipid Modifying Agents · 2Antianemic, Iron & All Combination · 2Angiotensin-Ii Antagonists, Combinations · 2Other Vitamins · 1Cardiac Care · 1Antianemic, Iron Preparations · 1Psycholeptics; Antipsychotics, Anxiolytics, Hypnotics And Sedatives · 1Antivirals For Systemic Use · 1Diuretic · 1Vitamin B1, & Combinations Of B1, B6, B12 · 1

Conditions treated

Hypertension · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official2 products · Rs 5,806.87 – Rs 6,435.16
Servaid1 products · Rs 230 – Rs 230
Median across source: Rs 6,121.01

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

NEUTRO PHARMA (PVT) LTD.29 shared molecules
Albro Pharmaceuticals28 shared molecules
VALOR PHARMACEUTICALS27 shared molecules
WEBROS PHARMACEUTICALS27 shared molecules
FYNK PHARMACEUTICALS27 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Wilshire Laboratories (Private) Limited holds 130 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmlodipineAmoxicillinAmoxycillin
NEUTRO PHARMA (PVT) LTD. holds 126 molecules not in this portfolio
AcetylcysteineAcyclovirAlbendazoleAmikacinAnastrazoleAnastrozole
Albro Pharmaceuticals holds 21 molecules not in this portfolio
AdapaleneAdapleneBetamethasoneClindamycinClioquinolDesloratadine

Get the full profile for TAGMA

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.